5-chloro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzaldehyde | 1310532-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-chloro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzaldehyde
• 英文别名: 5-chloro-2-(3-methyl-1,2,4-triazol-1-yl)benzaldehyde
• CAS: 1310532-06-9
• 化学式: C₁₀H₈ClN₃O
• 分子量: 221.646
• InChiKey: ZOSBTTZWQJDLRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-甲基-1H-1,2,4-噻唑 、 5-氯-2-氟苯甲醛 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 4.0h， 以20%的产率得到5-chloro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzaldehyde
  参考文献：
  名称：

  第ＸＩＡ因子阻害剤としてのジヒドロピリドンＰ１

  摘要：

  This invention provides compounds represented by formula (X): (X), wherein all variable groups are as defined in the specification, compounds, or their stereoisomers, tautomers, or pharmaceutically acceptable salts. These compounds are selective factor XIa inhibitors or dual inhibitors of factor XIa and plasma kallikrein. The invention also relates to pharmaceutical compositions containing these compounds and methods for treating thrombotic and/or inflammatory disorders using them.

  公开号：

  JP2015528022A

文献信息

• [EN] BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BENZIMIDAZOLE DE LA PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011068821A1

  公开（公告）日：2011-06-09

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药用盐，其中R1-R7如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和紊乱的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION
  申请人：CHEN Zhidong

  公开号：US20110301161A1

  公开（公告）日：2011-12-08

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salt thereof, wherein R 1 -R 7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其中R1-R7如本文所定义。本发明还涉及包括这些化合物的药物组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。
• DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150203492A1

  公开（公告）日：2015-07-23

  The present invention provides compounds of Formula (X): (Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了X式化合物：（X式，或其立体异构体、互变异构体或药学上可接受的盐），其中所有变量均如定义所述。这些化合物是选择性因子XIa抑制剂或FXIa和血浆卡利肌酶的双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Dihydropyridone p1 as factor XIa inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US09409908B2

  公开（公告）日：2016-08-09

  The present invention provides compounds of Formula (X):(Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了X式化合物：(X式化合物，或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量均如定义所述。这些化合物是选择性因子XIa抑制剂或FXIa和血浆卡利肌酶双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞性和/或炎症性疾病的方法。
• BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2509975B1

  公开（公告）日：2014-04-23